Status:
TERMINATED
A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
Lead Sponsor:
Meghan McCormick
Conditions:
Pediatric Cancer
Thrombocytopenia
Eligibility:
All Genders
2-21 years
Phase:
PHASE1
PHASE2
Brief Summary
This study evaluates the use of tranexamic acid (TXA) in addition to standard therapy in children receiving chemotherapy or blood and/or marrow transplantation to decrease the risk of bleeding. Half o...
Detailed Description
The purpose of this study is to conduct a prospective, randomized, blinded, placebo controlled trial to evaluate the safety and feasibility of the addition of antifibrinolytic therapy with tranexamic ...
Eligibility Criteria
Inclusion
- Patients must have a confirmed diagnosis of hematologic malignancy or solid tumor malignancy
- Patients must be undergoing or planned chemotherapy or BMT
- Patients will only be eligible to receive study drug or placebo during inpatient periods
- Patients must be predicted to have thrombocytopenia ≤20,000/microliter (uL) for ≥5 days
- Patient must have a platelet transfusion threshold of ≤30,000/uL
- Patients must be \>14 days beyond their last dose of Pegylated(PEG)-Asparaginase or \>72 hours beyond their last dose of Erwinia Asparaginase
- Patients must be able to comply with treatment and monitoring
Exclusion
- Diagnosis of acute promyelocytic leukemia (APL)
- History of Immune Thrombocytopenic Purpura (ITP), Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS)
- Diagnosis of Disseminated Intravascular Coagulopathy (DIC)
- History of inherited or acquired bleeding disorder AND/OR inherited or acquired prothrombotic disorder
- Patient must not have WHO Grade 2 bleeding or greater within 48 hours prior to enrollment or study drug activation
- Patient must not have received PEG-Asparaginase within the 7 day period prior to enrollment. If given within the 8-14 day period prior to enrollment patients are eligible if prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR) and fibrinogen are obtained and are within 1.5 times the upper limits of normal.
- Patient must not be receiving tranexamic acid or other anti-fibrinolytic agent or any other agent to promote hemostasis (which includes DDAVP, recombinant Factor VII, Prothrombin Complex Concentrate, Estrogen Derivatives and Progestins)
- Patient must not be receiving therapy with anticoagulation or antiplatelet therapy (which includes heparin infusion, enoxaparin, aspirin. If anticoagulant/antiplatelet therapy is discontinued when platelet count is \<50,000/uL patient will be eligible for enrollment)
- Patient must not be receiving platelet growth factors
- Current thromboembolic event
- History of thromboembolic event \<6 months prior to enrollment
- Current/prior history of sinusoidal obstruction disease
- Visible hematuria
- Renal dysfunction (as defined by age-specific creatinine values calculated by Schwartz equation) or hemodialysis or anuria (defined as \<10 mL urine/hour over 24 hours)
- History of seizures
- Allergy to tranexamic acid
- Pregnancy
- Unwilling to accept blood product transfusions
Key Trial Info
Start Date :
April 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 25 2020
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03806556
Start Date
April 22 2019
End Date
August 25 2020
Last Update
September 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Childrens Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224